Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome

Verena Wais,Lukas Kündgen,Stephan R. Bohl,S. von Harsdorf,Richard F. Schlenk,K Döhner,Veronica Teleanu,Lars Bullinger,T.M. Nguyen,Kathrin Drognitz,J C Moulin,Martin Binnenhei,Martin Bentz,Hartmut Döhner,D Bunjes,Florian Kuchenbauer,Mark Ringhoffer

Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome

2018

Verena Wais
Lukas Kündgen
Stephan R. Bohl
S. von Harsdorf
Richard F. Schlenk
K Döhner
Veronica Teleanu
Lars Bullinger
T.M. Nguyen
Kathrin Drognitz
J C Moulin
Martin Binnenhei
Martin Bentz
Hartmut Döhner
D Bunjes
Florian Kuchenbauer
Mark Ringhoffer

Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome

Keywords:

Diabetes mellitus
Oncology
Immunology
Cell
Transplantation
Toxicity
Internal medicine
Disease
Melphalan
Medicine
Haematopoiesis
Fludarabine
hematopoietic cell
reduced toxicity conditioning

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations